TCIM
ITCI

TIAA CREF Investment Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

TIAA CREF Investment Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$1.24M Buy
101,665
+3,988
+4% +$51K ﹤0.01% 2221
2018
Q4 		$1.11M Buy
97,677
+11,715
+14% +$189K ﹤0.01% 2243
2018
Q3 		$1.86M Sell
85,962
-46,538
-35% -$973K ﹤0.01% 2152
2018
Q2 		$2.34M Sell
132,500
-87,173
-40% -$1.77M ﹤0.01% 2085
2018
Q1 		$4.62M Buy
219,673
+45,053
+26% +$878K ﹤0.01% 1598
2017
Q4 		$2.53M Buy
174,620
+66,464
+61% +$1.03M ﹤0.01% 2002
2017
Q3 		$1.71M Sell
108,156
-2,769
-2% -$40.6K ﹤0.01% 2250
2017
Q2 		$1.38M Sell
110,925
-29,155
-21% -$338K ﹤0.01% 2390
2017
Q1 		$2.28M Sell
140,080
-2,179
-2% -$31.5K ﹤0.01% 2056
2016
Q4 		$2.15M Sell
142,259
-6,672
-4% -$94.2K ﹤0.01% 2151
2016
Q3 		$2.27M Sell
148,931
-2,335
-2% -$94.4K ﹤0.01% 2099
2016
Q2 		$5.87M Buy
151,266
+25,751
+21% +$925K ﹤0.01% 1419
2016
Q1 		$3.49M Buy
125,515
+15,245
+14% +$508K ﹤0.01% 1746
2015
Q4 		$5.93M Buy
110,270
+22,284
+25% +$1.12M ﹤0.01% 1442
2015
Q3 		$3.52M Sell
87,986
-6,528
-7% -$213K ﹤0.01% 1783
2015
Q2 		$3.02M Buy
94,514
+30,025
+47% +$761K ﹤0.01% 2034
2015
Q1 		$1.54M Sell
64,489
-2,033
-3% -$45.5K ﹤0.01% 2384
2014
Q4 		$1.17M Buy
66,522
+1,797
+3% +$28.1K ﹤0.01% 2566
2014
Q3 		$887K Hold
64,725
– – ﹤0.01% 2704
2014
Q2 		$1.09M Buy
+64,725
New +$1.07M ﹤0.01% 2676

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return

TIAA CREF Investment Management's ITCI Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Intra-Cellular Therapies Inc. (ITCI) stake by 4.1% in Q1 2019, buying an estimated $51K and bringing the position to 101,665 shares worth $1.24M. The position accounts for ﹤0.01% of the portfolio, ranked #2221.

TIAA CREF Investment Management first reported a position in ITCI in Q2 2014 and has held it in 20 quarters since. The position peaked at $5.93M in Q4 2015. 127 funds tracked by Wall St. Rank hold ITCI as of Q1 2019.

  • TIAA CREF Investment Management held 101,665 shares of Intra-Cellular Therapies Inc. worth $1.24M as of Q1 2019.
  • TIAA CREF Investment Management bought 3,988 Intra-Cellular Therapies Inc. shares in Q1 2019, an estimated $51K.
  • Intra-Cellular Therapies Inc. made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2221 holding.
  • TIAA CREF Investment Management first reported a position in Intra-Cellular Therapies Inc. in Q2 2014 and has held it in 20 quarters since.
  • TIAA CREF Investment Management's Intra-Cellular Therapies Inc. position peaked at $5.93M in Q4 2015.
  • 127 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.